{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:17:32Z","timestamp":1790201852990,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate fixed compared with weight-based enoxaparin dosing to achieve prophylactic anti-Xa levels after cesarean delivery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>Individuals meeting institutional criteria for enoxaparin thromboprophylaxis after cesarean delivery were randomly allocated to fixed (40 mg daily for body mass index [BMI, calculated as weight in kilograms divided by height in meters squared] lower than 40; 40 mg every 12 hours for BMI 40 or higher) or weight-based (0.5 mg\/kg every 12 hours) enoxaparin dosing. Enoxaparin was initiated during inpatient hospitalization and continued at discharge for 14 days. Those with contraindication to anticoagulation, plan for therapeutic anticoagulation, or known renal impairment were excluded. The trial was unmasked. The primary outcome was prophylactic (0.2\u20130.6 international units\/mL) peak anti-Xa level 4\u20136 hours after at least the third enoxaparin dose (at steady state). Secondary outcomes included subprophylactic and supraprophylactic peaks, outpatient peak, and venous thromboembolism (VTE) and wound complications in the first 6 weeks postpartum. Sample size of 121 per group was planned. At interim analysis with 50% enrollment, the trial was stopped early for efficacy. Primary analyses followed intention-to-treat principle with worst-case imputation for missing outcomes. Secondary analyses were complete case.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>From June 2020 to November 2021, 74 individuals were randomized to weight-based enoxaparin and 72 to fixed-dose enoxaparin. Those who received weight-based dosing were more likely to achieve prophylactic anti-Xa levels than those who received fixed dosing in primary analysis (49\/74 [66%] vs 32\/72 [44%], relative risk [RR] 1.49, 95% CI 1.10\u20132.02) and secondary analysis (49\/60 [82%] vs 32\/57 [56%], RR 1.45, 95% CI 1.12\u20131.88). Subprophylactic levels occurred more frequently with fixed dosing; supraprophylactic levels did not differ significantly by dosing. At the outpatient postoperative visit, 52% of participants (15\/29) with weight-based dosing compared with 15% (5\/33) with fixed dosing achieved prophylactic peak anti-Xa level (RR 3.41, 95% CI 1.42\u20138.24). There were no VTEs in either group. Wound complications occurred in five individuals (7%) with weight-based enoxaparin dosing compared with one individual (1%) with fixed enoxaparin dosing (RR 4.86, 95% 0.58\u201340.63).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Weight-based dosing was more effective than fixed enoxaparin dosing in achieving prophylactic peak anti-Xa levels after cesarean delivery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT04305756.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004937","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T21:02:06Z","timestamp":1662670926000},"page":"575-583","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery"],"prefix":"10.1097","volume":"140","author":[{"given":"Ann M.","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Allshouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ware","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Y.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torri D.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/AOG.0000000000002062","article-title":"The case for a national maternal mortality review committee","volume":"130","author":"Clark","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/AOG.0000000000002851","article-title":"Eliminating preventable maternal deaths in the United States: progress made and next steps","volume":"132","author":"Metz","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/AOG.0000000000000230","article-title":"Postpartum venous thromboembolism: incidence and risk factors","volume":"123","author":"Tepper","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08956.x","article-title":"Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study","volume":"156","author":"Sultan","year":"2012","journal-title":"Br J Haematol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa1311485","article-title":"Risk of a thrombotic event after the 6-week postpartum period","volume":"370","author":"Kamel","year":"2014","journal-title":"N Engl J Med"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"36.e1","DOI":"10.1016\/j.ajog.2008.03.007","article-title":"Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery","volume":"199","author":"Clark","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11239-015-1309-0","article-title":"Guidance for the treatment and prevention of obstetric-associated venous thromboembolism","volume":"41","author":"Bates","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/AOG.0000000000001579","article-title":"National partnership for maternal safety: consensus bundle on venous thromboembolism","volume":"128","author":"D'Alton","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.ajog.2020.04.032","article-title":"Society for Maternal-Fetal Medicine Consult Series #51: thromboembolism prophylaxis for cesarean delivery","volume":"223","author":"Pacheco","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/jp.2015.130","article-title":"A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women","volume":"36","author":"Stephenson","year":"2016","journal-title":"J Perinatol"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/AOG.0000000000000873","article-title":"Enoxaparin dosing after cesarean delivery in morbidly obese women","volume":"125","author":"Overcash","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"151221","DOI":"10.1016\/j.semperi.2020.151221","article-title":"Drugs in pregnancy: pharmacologic and physiologic changes that affect clinical care","volume":"44","author":"Pinheiro","year":"2020","journal-title":"Semin Perinatol"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0002-9378(99)70091-8","article-title":"Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy","volume":"181","author":"Casele","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MBC.0000000000000573","article-title":"The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study","volume":"28","author":"Boban","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.23228","article-title":"Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity","volume":"87","author":"Freeman","year":"2012","journal-title":"Am J Hematol"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.thromres.2009.02.003","article-title":"Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients","volume":"125","author":"Rondina","year":"2010","journal-title":"Thromb Res"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijoa.2013.05.008","article-title":"Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study","volume":"22","author":"Hiscock","year":"2013","journal-title":"Int J Obstet Anesth"},{"key":"R24-20250423","first-page":"530","article-title":"Evaluation of a risk-stratified, heparin-based, obstetric thromboprophylaxis protocol","volume":"138","author":"Lu","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/1471-0528.15150","article-title":"Postpartum venous thromboembolism prophylaxis may cause more harm than benefit: a critical analysis of international guidelines through an evidence-based lens","volume":"125","author":"Kotaska","year":"2018","journal-title":"BJOG"},{"key":"R26-20250423","first-page":"527","article-title":"Postpartum heparin thromboprophylaxis: more harm than good","volume":"138","author":"Kotaska","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R28-20250423","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/AOG.0000000000000007","article-title":"Underuse of postcesarean thromboembolism prophylaxis","volume":"122","author":"Friedman","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R29-20250423","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/1471-0528.13706","article-title":"A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major guidelines","volume":"123","author":"Palmerola","year":"2016","journal-title":"BJOG"},{"key":"R30-20250423","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jama.2021.9941","article-title":"Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement","volume":"326","author":"Orkin","year":"2021","journal-title":"JAMA"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:04:30Z","timestamp":1745435070000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004937"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004937","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"2022-05-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}